Outcome including U-MRD in frontline CLL
| Outcome . | FCR3 (N = 408) . | CLB/Obinutuzumab5 (N = 216) . | Venetoclax/Obinutuzumab5 (N = 216) . | Ibrutinib/Venetoclax6 (N = 80) . |
|---|---|---|---|---|
| ORR, % | 90 | 71 | 85 | 100 |
| CR, % | 44 | 23 | 50 | 96 |
| U-MRD4 (PB), % | 63 | 35 | 76 | n.d. |
| U-MRD6 (PB), % | n.d. | 7 | 42 | n.d. |
| U-MRD4 (BM), % | 44 | 17 | 57 | 69 |
| U-MRD6 (BM), % | n.d. | n.d. | n.d. | n.d. |
| Median PFS (mo) | 56.8 (at median follow-up of 5.9 y) | n.r. (at month 24, 64% were progression free) | n.r. (at month 24, 88% were progression free) | n.r. (at month 12, 98% were progression free) |
| Median OS (mo) | n.r. (at median follow-up of 5.9 y) | n.r. (at month 24, 93% were alive) | n.r. (at month 24, 92% were alive) | n.r. (at month 12, 99% were alive) |
| Outcome . | FCR3 (N = 408) . | CLB/Obinutuzumab5 (N = 216) . | Venetoclax/Obinutuzumab5 (N = 216) . | Ibrutinib/Venetoclax6 (N = 80) . |
|---|---|---|---|---|
| ORR, % | 90 | 71 | 85 | 100 |
| CR, % | 44 | 23 | 50 | 96 |
| U-MRD4 (PB), % | 63 | 35 | 76 | n.d. |
| U-MRD6 (PB), % | n.d. | 7 | 42 | n.d. |
| U-MRD4 (BM), % | 44 | 17 | 57 | 69 |
| U-MRD6 (BM), % | n.d. | n.d. | n.d. | n.d. |
| Median PFS (mo) | 56.8 (at median follow-up of 5.9 y) | n.r. (at month 24, 64% were progression free) | n.r. (at month 24, 88% were progression free) | n.r. (at month 12, 98% were progression free) |
| Median OS (mo) | n.r. (at median follow-up of 5.9 y) | n.r. (at month 24, 93% were alive) | n.r. (at month 24, 92% were alive) | n.r. (at month 12, 99% were alive) |
BM, bone marrow; CLB, chlorambucil; CR, complete remission; n.d., not detected; n.r. = not reached; ORR, overall response rate; OS, overall survival; PB, peripheral blood.